November 3, 2015
Janssen Applys to EMA to Expand Use of Imbruvica
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seeking…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 3, 2015
OptiBiotix files two new cholesterol reducing patents
OptiBiotix Health has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.
November 3, 2015
Faron Pharmaceuticals secures Clevegen production with Swiss Selexis
Finland’s Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has entered into an agreement with Swiss-based Selexis SA for producing Novel Cancer Immunotherapy Clevegen.
November 3, 2015
Sanofi and BioNTech Announce Cancer Immunotherapy Collaboration and License Agreement
Sanofi and BioNTech A.G. have entered into a multiyear exclusive collaboration and license agreement.
November 2, 2015
Bayer’s flupyradifurone approved by EC
Bayer CropScience has reached an important milestone towards the market introduction of its innovative insecticide Sivanto prime in Europe.
November 2, 2015
Lilly expands its Indianapolis R&D headquartes
Eli Lilly and Company has revealed plans to expand its global research and development (R&D) headquarters in Indianapolis, Indiana.
October 30, 2015
NIH researchers link single gene variation to obesity
A single variation in the gene for brain-derived neurotropic factor (BDNF) may influence obesity in children and adults, according to a new study funded by the National Institutes of Health.
October 30, 2015
Bayer’s Eylea approved for Myopic CNV
Eylea is now also approved for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV).
October 30, 2015
Lonsurf for colerectal cancer patients approved by FDA
United States Food and Drug Administration (FDA) has approved Lonsurf (trifluridine and tipiracil) tablets for the treatment of patients with metastatic colorectal cancer who have been previously…
October 30, 2015
Allergan, Pfizer in merger talks
Allergan plc has confirmed that it has been approached by Pfizer Inc. and is in preliminary friendly discussions regarding a potential business combination transaction.